ArticleCureus2024
Management and Diagnosis of Empagliflozin-Induced Burning Mouth Syndrome: A Case Report.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Metabolic Syndrome and Periodontitis-From Shared Mechanisms to Interdisciplinary Care: A Narrative Review of Clinical Evidence.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Burning mouth syndrome (BMS) poses a significant clinical challenge. Patients often present with symptoms that can severely affect their quality of life, leading to anxiety, depression, and social withdrawal. The etiology of BMS remains poorly understood, which complicates its diagnosis and treatment. This case report describes an 80-year-old woman who presented with BMS following the administration of empagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor used for glycemic control, along with its benefits in the progression and prognosis of cardiac insufficiency and chronic renal disease. Despite multiple treatments, her symptoms persisted until empagliflozin withdrawal, resulting in significant improvement at the six-month follow-up. This report suggests a potential association between empagliflozin and BMS, underscoring the need for clinicians to be vigilant regarding drug-related etiologies in the diagnosis and management of oral symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.